Cargando…
Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
Understanding the duration of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody Response Survey (Texas CARES) with at least 1 nucleocapsid protei...
Autores principales: | Swartz, Michael D, DeSantis, Stacia M, Yaseen, Ashraf, Brito, Frances A, Valerio-Shewmaker, Melissa A, Messiah, Sarah E, Leon-Novelo, Luis G, Kohl, Harold W, Pinzon-Gomez, Cesar L, Hao, Tianyao, Zhang, Shiming, Talebi, Yashar, Yoo, Joy, Ross, Jessica R, Gonzalez, Michael O, Wu, Leqing, Kelder, Steven H, Silberman, Mark, Tuzo, Samantha, Pont, Stephen J, Shuford, Jennifer A, Lakey, David, Boerwinkle, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833436/ https://www.ncbi.nlm.nih.gov/pubmed/35514141 http://dx.doi.org/10.1093/infdis/jiac167 |
Ejemplares similares
-
Strategies to Estimate Prevalence of SARS-CoV-2 Antibodies in a Texas Vulnerable Population: Results From Phase I of the Texas Coronavirus Antibody Response Survey
por: Valerio-Shewmaker, Melissa A., et al.
Publicado: (2021) -
Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region
por: DeSantis, Stacia M., et al.
Publicado: (2022) -
SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents
por: Messiah, Sarah E., et al.
Publicado: (2023) -
Clinical epidemiology of carbapenem-resistant Enterobacterales in the Greater Houston region of Texas: a 6-year trend and surveillance analysis
por: Tadese, Bekana K., et al.
Publicado: (2022) -
1792. SARS-CoV-2 Genomic Surveillance System Development as a Model for Other Emerging Pathogens in Texas
por: Rai, Saroj, et al.
Publicado: (2023)